NCT02481141View on ClinicalTrials.gov

Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes

NACompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

5-ALA-SFC

Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC

DRUG

Placebo

All Listed Sponsors
lead

SBI Pharmaceuticals Co, Ltd.

INDUSTRY

NCT02481141 - Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes | Biotech Hunter | Biotech Hunter